Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Improved prostate cancer grading by incorporating Gleason pattern quantification, invasive cribriform and intraductal carcinoma in the new QUICC-score.

Annals of diagnostic pathology·2026

Same author

Use of Artificial Intelligence in prostate MRI: A rapid scoping review highlighting limited evidence in screening context.

European journal of radiology·2026

Same author

Who, When, and How: Watchful Waiting in the ERSPC Rotterdam.

European urology open science·2026

Same author

Prostate cancer mortality among men with and without comorbidity: Long-term results from the European randomized study of screening for prostate cancer Rotterdam.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Empowering choices: insights from healthcare professionals on shared decision-making in kidney cancer.

BJU international·2026

Same author

Cell-Based Immunization Combined with Single-Round Cell Panning Enables Discovery of PSMA-Targeting Nanobodies from Phage Display Libraries.

Biomolecules·2026

Search research articles

Related Experiment Video

Updated: May 14, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Active surveillance: oncologic outcome.

Lionne D F Venderbos¹, Leonard P Bokhorst, Chris H Bangma

¹Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands. l.venderbos@erasmusmc.nl

Current Opinion in Urology

|February 22, 2013

Summary

This summary is machine-generated.

Active surveillance for prostate cancer is safe, with very low mortality rates. Postponing treatment for most men does not compromise oncologic outcomes, avoiding overtreatment.

More Related Videos

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Related Experiment Videos

Last Updated: May 14, 2026

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Area of Science:

Oncology
Urology
Men's Health

Background:

Active surveillance is an established strategy for managing low-risk prostate cancer.
Concerns remain regarding the long-term oncologic outcomes and potential overtreatment with radical therapies.

Purpose of the Study:

To review recent literature (12-18 months) on oncologic outcomes for men undergoing active surveillance for prostate cancer.
To assess the impact of active surveillance on disease-specific mortality and intermediate outcomes.

Main Methods:

Systematic review of recent published trials comparing radical prostatectomy with watchful waiting.
Analysis of data on prostate cancer-specific mortality and intermediate outcomes under active surveillance.

Main Results:

Radical treatment benefits only a small proportion of men; many are overtreated.
Active surveillance aims to postpone treatment for most men while maintaining low disease-specific mortality.
Recent data show very low prostate cancer-specific mortality under active surveillance, with similar outcomes to immediate radical treatment.

Conclusions:

Active surveillance demonstrates very low prostate cancer-specific mortality, though longer follow-up is needed.
Postponing treatment in active surveillance does not appear to negatively impact oncologic outcomes.
The majority of men can avoid active treatment without compromising oncologic outcomes.